| Breast cancer mortality after a diagnosis of ductal carcinoma in situ SA Narod, J Iqbal, V Giannakeas, V Sopik, P Sun JAMA oncology 1 (7), 888-896, 2015 | 655 | 2015 |
| Low-grade serous ovarian cancer: a review A Kaldawy, Y Segev, O Lavie, R Auslender, V Sopik, SA Narod Gynecologic oncology 143 (2), 433-438, 2016 | 207 | 2016 |
| Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis C Cybulski, W Kluźniak, T Huzarski, D Wokołorczyk, A Kashyap, ... The Lancet Oncology 16 (6), 638-644, 2015 | 183 | 2015 |
| The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer V Sopik, SA Narod Breast cancer research and treatment 170, 647-656, 2018 | 167 | 2018 |
| Ten-year survival in women with primary stage IV breast cancer LG Eng, S Dawood, V Sopik, B Haaland, PS Tan, N Bhoo-Pathy, ... Breast cancer research and treatment 160, 145-152, 2016 | 124 | 2016 |
| Why have ovarian cancer mortality rates declined? Part I. Incidence V Sopik, J Iqbal, B Rosen, SA Narod Gynecologic oncology 138 (3), 741-749, 2015 | 118 | 2015 |
| BRCA1 and BRCA2 mutations and the risk for colorectal cancer V Sopik, C Phelan, C Cybulski, SA Narod Clinical genetics 87 (5), 411-418, 2015 | 108 | 2015 |
| International variation in breast cancer incidence and mortality in young women V Sopik Breast Cancer Research and Treatment 186, 497-507, 2021 | 93 | 2021 |
| Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ V Sopik, P Sun, SA Narod Breast cancer research and treatment 167, 787-795, 2018 | 86 | 2018 |
| Why have ovarian cancer mortality rates declined? Part II. Case-fatality V Sopik, J Iqbal, B Rosen, SA Narod Gynecologic oncology 138 (3), 750-756, 2015 | 67 | 2015 |
| Is invasion a necessary step for metastases in breast cancer? SA Narod, V Sopik Breast cancer research and treatment 169, 9-23, 2018 | 65 | 2018 |
| Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer J Lerner-Ellis, S Khalouei, V Sopik, SA Narod Expert review of anticancer therapy 15 (11), 1315-1326, 2015 | 59 | 2015 |
| Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland C Cybulski, J Lubiński, D Wokołorczyk, W Kuźniak, A Kashyap, V Sopik, ... Clinical genetics 88 (4), 366-370, 2015 | 58 | 2015 |
| Association of a diagnosis of ductal carcinoma in situ with death from breast cancer V Giannakeas, V Sopik, SA Narod JAMA Network Open 3 (9), e2017124-e2017124, 2020 | 54 | 2020 |
| Genetic testing for RAD51C mutations: in the clinic and community V Sopik, MR Akbari, SA Narod Clinical genetics 88 (4), 303-312, 2015 | 53 | 2015 |
| The relationship between local recurrence and death in early-stage breast cancer V Sopik, S Nofech-Mozes, P Sun, SA Narod Breast cancer research and treatment 155, 175-185, 2016 | 51 | 2016 |
| Association of radiotherapy with survival in women treated for ductal carcinoma in situ with lumpectomy or mastectomy V Giannakeas, V Sopik, SA Narod JAMA network open 1 (4), e181100-e181100, 2018 | 50 | 2018 |
| Why have ovarian cancer mortality rates declined? Part III. Prospects for the future V Sopik, B Rosen, V Giannakeas, SA Narod Gynecologic Oncology 138 (3), 757-761, 2015 | 46 | 2015 |
| Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland P Wojcik, M Jasiówka, E Strycharz, M Sobol, D Hodorowicz-Zaniewska, ... Hereditary cancer in clinical practice 14, 1-10, 2016 | 43 | 2016 |
| The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients V Sopik, P Sun, SA Narod Breast cancer research and treatment 165, 391-402, 2017 | 42 | 2017 |
